), acute bronchitis, pneumonia, secondary infection of chronic respiratory lesions, otitis media, sinusitis
Dosage / dose Usually, oral administration of 400 mg once a day as galenoxacin in adults。
Characteristic
1. It has an antibacterial spectrum and excellent antimicrobial activity suitable for the main phytopathogenic bacteria of respiratory / otolaryngology area infection (in vitro).
2. It also shows excellent antimicrobial activity against multidrug-resistant S. pneumoniae (in vitro).
3. Even when administered once a day, a large AUC (area under the blood concentration curve) is obtained and shows good migration to body fluids and tissues.
Four. It shows an excellent clinical effect with once-daily administration to respiratory / otorhinolaryngology area infections.
Five. In S. pneumoniae and Staphylococcus aureus, resistant mutants are difficult to appear (in vitro).
6. Side effects were observed in 132 (18.80%) out of 702 subjects subject to safety assessment in clinical trials carried out in Japan by the time of approval, and abnormal laboratory test values were found in 211 cases (30.06%).
Approval acquirer Toyama Chemical Industry Co., Ltd.
Packaging tablets 200 mg: 100 tablets (PTP), 500 tablets (PTP, roses)
Drug price listing date September 21, 2007
Release date October 5, 2007
|
